As for HLA-E expression profile, no significant relationship was observed between the density of CD94+ intraepithelial lymphocytes and the objective response to cetuximab at 3 months, regardless of the tumor site (primary or metastatic). This evidence concerns the gene KLRD1 and neoplasm.